Immunity against tetanus and diphtheria after childhood sarcoma treatment.
M
M
Paulides
W
W
Stöhr
H-Jürgen
HJ
Laws
N
N
Graf
M
M
Lakomek
F
F
Berthold
K
K
Schmitt
F
F
Niggli
H
H
Jürgens
S
S
Bielack
E
E
Koscielniak
T
T
Klingebiel
T
T
Langer
D000293:Adolescent; D000367:Age Factors; D000907:Antibodies, Bacterial / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D004165:Diphtheria / Q000276:immunology*; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D008297:Male; D009894:Opportunistic Infections / Q000276:immunology; D012516:Osteosarcoma / Q000188:drug therapy* / Q000276:immunology*; D011159:Population Surveillance; D011446:Prospective Studies; D012042:Registries; D012307:Risk Factors; D012509:Sarcoma / Q000188:drug therapy* / Q000276:immunology*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D013742:Tetanus / Q000276:immunology*
D000907:Antibodies, Bacterial; D000970:Antineoplastic Agents